Magnetic resonance imaging/positron emission tomography provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration

International Journal of Gynecological Cancer

Volumn 23, Issue 8, 2013, Pages 1512-1519

  Vargas, Hebert Alberto ^a   Burger, Irene A ^a   Donati, Olivio F ^a,b   Andikyan, Vaagn ^a   Lakhman, Yulia ^a   Goldman, Debra A ^a   Schöder, Heiko ^a   Chi, Dennis S ^a   Sala, Evis ^a   Hricak, Hedvig ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cancer recurrence; Cervical cancer; Endometrial cancer; MRI; MRI PET fusion; Pelvic exenteration; PET

Indexed keywords

DIATRIZOATE; FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; BLADDER METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GYNECOLOGIC CANCER; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; INSTITUTIONAL REVIEW; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS CANCER; PELVIS EXENTERATION; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTUM CANCER; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; PELVIC EXENTERATION; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; UTERINE NEOPLASMS; VULVAR NEOPLASMS;

EID: 84888235283     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a41e61     Document Type: Article

References (19)

1. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/ CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357-4368.
2. Donati OF, Hany TF, Reiner CS, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010;51:692-699.
3. Vaska P, Cao T. The state of instrumentation for combined positron emission tomography and magnetic resonance imaging. Semin Nucl Med. 2013;43:11-18.
4. Khoury-Collado F, Einstein MH, Bochner BH, et al. Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol. 2012;124:42-47.
5. Schmidt AM, Imesch P, Fink D, et al. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecol Oncol. 2012;125:604-609.
6. Park JY, Choi HJ, Jeong SY, et al. The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: analysis of risk factors predicting recurrence and survival. J Surg Oncol. 2007;96:560-568.
7. Popovich MJ. The role of MR imaging in determining surgical eligibility for pelvic exenteration. AJR Am J Roentgenol. 1993;160:525-531.
8. Rockall AG. Can MRI rule out bladder and rectal invasion in cervical cancer to help select patients for limited EUA? Gynecol Oncol. 2006;101:244-249.
9. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
10. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
11. Andikyan V, Khoury-Collado F, Gerst SR, et al. Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: review of surgical technique, complications, and outcome. Gynecol Oncol. 2012;126:346-350.
12. Andikyan V, Khoury-Collado F, Sonoda Y, et al. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery. Gynecol Oncol. 2012;125:404-408.
13. Hawighorst-Knapstein S, Fusshoeller C, Franz C, et al. The impact of treatment for genital cancer on quality of life and body imageVresults of a prospective longitudinal 10-year study. Gynecol Oncol. 2004;94:398-403.
14. Roos EJ, de Graeff A, van Eijkeren MA, et al. Quality of life after pelvic exenteration. Gynecol Oncol. 2004;93:610-614.
15. Shingleton HM. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol. 1989;73:1027-1034.
16. Wassberg C, Akin O, Vargas HA, et al. The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol. 2012;199:360-366.
17. Futterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology. 2005;237:541-549.
18. Husain A, Akhurst T, Larson S, et al. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol. 2007;106:177-180.
19. Burger IA, Vargas HA, Donati OF, et al. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecol Oncol. 2013;129:586-592.